Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)

MLA

Susanne Jung, et al. “Protocol of a First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the Bispecific CD276xCD3 Antibody CC-3 in Patients with Colorectal Cancer (CoRe_CC-3).” Frontiers in Oncology, vol. 14, Feb. 2024. EBSCOhost, https://doi.org/10.3389/fonc.2024.1351901.

APA

Susanne Jung, Richard F. Schlenk, Christopher Hackenbruch, Sandra S.L. Roldan Pinzon, Michael Bitzer, Martin Pflügler, Juliane S. Walz, Gundram Jung, Jonas S. Heitmann, & Helmut R. Salih. (2024). Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3). Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1351901

Chicago

Susanne Jung, Richard F. Schlenk, Christopher Hackenbruch, Sandra S.L. Roldan Pinzon, Michael Bitzer, Martin Pflügler, Juliane S. Walz, Gundram Jung, Jonas S. Heitmann, and Helmut R. Salih. 2024. “Protocol of a First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the Bispecific CD276xCD3 Antibody CC-3 in Patients with Colorectal Cancer (CoRe_CC-3).” Frontiers in Oncology 14 (February). doi:10.3389/fonc.2024.1351901.